Latest stories on NKTR
NEKTAR THERAPEUTICS (NKTR) files 8-K
SEC 8-K50 · neutralgeneral
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire50 · neutralgeneral
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Nektar’s (NKTR) Billion-Dollar Balance Sheet Faces A Multi-Year Test
Yahoo Top48 · neutralgeneral
Rezpegaldesleukin Sets New Standard in Atopic Dermatitis After Meeting All Primary and Key Secondary Endpoints in Phase 2b Study
MarketChameleon76 · bullishproduct/pr
Nektar’s rezpegaldesleukin featured in published atopic dermatitis trial
The Fly59 · neutralproduct/pr
Nektar reinstated with a Neutral at JPMorgan
The Fly50 · neutralanalyst
Nektar Therapeutics’ Earnings Call Highlights Rezpeg Momentum
TipRanks56 · neutralearnings
Nektar (NKTR) Q2 2026 Earnings Call Transcript
The Motley Fool63 · neutralearnings
Nektar reports Q2 EPS ($1.23), consensus ($2.04)
The Fly28 · bearishearnings
Nektar: Maintaining 'Strong Buy' Rating Due To REZPEG Catalyst, Another Coming
Seeking Alpha73 · bullishanalyst
Nektar outlines REZPEG Phase III timeline with mid-2028 data and 2029 BLA plan
Seeking Alpha63 · neutralproduct/pr
Nektar Therapeutics (NKTR) Q2 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
NEKTAR THERAPEUTICS (NKTR) files 8-K
SEC 8-K50 · neutralgeneral
Nektar Therapeutics GAAP EPS of -$1.23 beats by $0.70, revenue of $10.13M misses by $0.34M
Seeking Alpha56 · neutralearnings
Nektar Therapeutics Announces Second Quarter 2026 Financial Results
PR Newswire50 · neutralgeneral
Kuehn Law Encourages Investors of Nektar Therapeutics to Contact Law Firm
PR Newswire44 · neutralgeneral
Nektar Therapeutics to Announce Q2 Results on August 13—Upcoming Earnings Call Brings Pipeline Focus Into Spotlight
July 29, 2026
MarketChameleon55 · neutralearnings
Nektar: Sanofi's Exit Clears A Competitor But Raises The Bar In Atopic Dermatitis
Seeking Alpha63 · neutralproduct/pr
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
StockTitan50 · neutralgeneral
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR Newswire50 · neutralgeneral
Nektar Therapeutics Launches Phase 3 ZENITH AD Trials—Rezpegaldesleukin Shows Promise in Hard-to-Treat Atopic Dermatitis
July 21, 2026
MarketChameleon67 · bullishproduct/pr